Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity

References

• Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):1–12.
   Web of Science ®Google Scholar
• Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943–953.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Kourtzelis I, Li X, Mitroulis I, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat Immunol. 2019;20(1):40–49.
   PubMed Web of Science ®Google Scholar
• Venakteshaiah SU, Kumar KH. Inflammation and cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(2):193–194.
   PubMed Web of Science ®Google Scholar
• Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–147.
   PubMed Web of Science ®Google Scholar
• Fishbein A, Hammock BD, Serhan CN, et al. Carcinogenesis: failure of resolution of inflammation? Pharmacol Ther. 2021;218:107670.
   PubMed Web of Science ®Google Scholar
• Yang Z, Jiang X, Zhang Z, et al. HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer. Cancer Gene Ther. 2021;28(1–2):141–155.
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916–927.
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol. 2020;31(11):1491–1505.
   PubMed Web of Science ®Google Scholar
• Li J, Wei Q, Wu X, et al. Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. Clin Transl Med. 2020;10(4):e118.
   PubMed Web of Science ®Google Scholar
• Lin Z, Xu Q, Miao D, et al. An inflammatory Response-Related gene signature can impact the immune status and predict the prognosis of hepatocellular carcinoma. Front Oncol. 2021;11:644416.
   PubMedGoogle Scholar
• Ishwaran H, Kogalur UB, Blackstone EH, et al. Random survival forests. In: Wiley StatsRef: statistics reference online. Chichester (UK): John Wiley & Sons Ltd; 2019.
   Google Scholar
• Michels N, van Aart C, Morisse J, et al. Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies. Crit Rev Oncol Hematol. 2021;157:103177.
   PubMed Web of Science ®Google Scholar
• Tan Z, Xue H, Sun Y, et al. The role of tumor inflammatory microenvironment in lung cancer. Front Pharmacol. 2021;12:688625.
   PubMed Web of Science ®Google Scholar
• Corren J, Ziegler SF. TSLP: from allergy to cancer. Nat Immunol. 2019;20(12):1603–1609.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wei C-Y, Chang K-K, et al. TSLP promotes angiogenesis of human umbilical vein endothelial cells by strengthening the crosstalk between cervical cancer cells and eosinophils. Oncol Lett. 2017;14(6):7483–7488.
   PubMed Web of Science ®Google Scholar
• Seok Y, Lee WK, Park JY, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients. Mol Cells. 2019;42(2):161–165.
   PubMed Web of Science ®Google Scholar
• Irigoyen M, Pajares MJ, Agorreta J, et al. TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer. 2010;9:130.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jiang G, Xu E, et al. Identification of SRXN1 and KRT6A as key genes in smoking-related non-small-cell lung cancer through bioinformatics and functional analyses. Front Oncol. 2021;11:810301.
   PubMed Web of Science ®Google Scholar
• Liu H, Kuang X, Zhang Y, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell. 2020;37(3):324.e328–339.e328.
   Web of Science ®Google Scholar